

Remarks

Claims 9, 12, 13, 24, and 28 have been amended to correct minor typographical errors or to correct an error with regard to SEQ ID NOS: 13 and 14.

The amendments to the paragraph on page 7 are made to correct a typographical error in the referenced patent application number. The application number, as corrected, is also cited elsewhere in the present application (*see* page 4, line 8). With regard to SEQ ID NOS:13 and 14, these sequences have been amended to identify where the non-naturally occurring residues are positioned. The correction of these peptide sequences is consistent with the peptide descriptions in WO 01/42281, which is incorporated by reference in its entirety into the present application (*see* page 14, lines 24-26).

In addition to the above-noted amendments, applicants request entry of the accompanying amended sequence listing. Pursuant to 37 CFR § 1.821 no new matter has been introduced.

In view of all of the foregoing, applicants request examination of all of the above-identified claims.

Respectfully submitted,

Date: April 9, 2007

/Edwin V. Merkel/

Edwin V. Merkel
Registration No. 40,087

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1128
Facsimile: (585) 263-1600